Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 198.00 | |
25 mg | In stock | $ 396.00 | |
50 mg | In stock | $ 663.00 | |
100 mg | In stock | $ 1,060.00 | |
500 mg | In stock | $ 2,120.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 133.00 |
Description | PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer. |
Targets&IC50 | EGFR tyrosine kinase:0.7 nM |
In vitro | PKI-166 (0–0.5 μM; 1 hour) pretreatment suppresses EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 (0.03μ M; 6 days) increased the cytotoxicity mediated by gemcitabine.[1] |
In vivo | PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) suppresses the growth of pancreatic cancer.[1] |
Molecular Weight | 330.38 |
Formula | C20H18N4O |
CAS No. | 187724-61-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (83.23 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PKI-166 187724-61-4 Angiogenesis Tyrosine Kinase/Adaptors VEGFR PKI 166 PKI166 inhibitor inhibit